C4X Discovery and Sanofi ink 414m IL-17A blocker R&D contract
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
Next-gen COVID-19 vaccine good in preclinical tests
/in News/by Thomas GabrielczykIntravacc has announced positive data for its nasal SARS-CoV-2 vaccine that embeds the viral spike antigen in bacterial Outer Membrane Vesicles (OMV)
EMA: AZD1222 causes serious rare ADEs
/in News/by Thomas GabrielczykIn a new statement, the EU regulatory authority EMA postulates that AstraZeneca’s vaccine causes serious deep vein thrombosis.
Targeting SARS-CoV-2 differently
/in News/by Thomas GabrielczykGerman structural biologists have identified seven compounds that neutralise SARS-CoV-2 by targeting Mpro, the virus main protease.
miRNAs unmask vulnerability in breast cancer stem cells
/in News/by Thomas GabrielczykResearchers in Italy have identified a pair of microRNA molecules, miR-146A and miR-, help maintain a population of breast cancer stem cells
Janssen to pledge COVID-19 vaccine to African Union
/in News/by Thomas GabrielczykJohnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT).
Bispecific IgG switch off SARS-CoV-2 escape variants
/in News/by Thomas GabrielczykA bispecific antibody designed by a Swiss-Czech research team suppressed viral escape of SARS-CoV-2 variants in animals.
Step Pharma SAS raises 35m in Series B
/in News/by Thomas GabrielczykKurma Partners-founded Step Pharma has baged 35m in a Series B financing to advance its blood cancer lead STP938.
AZD1222 claims 79% effecacy in pivotal US study
/in News/by Thomas GabrielczykFollowing assemingly good results in a Phase III study AstraZeneca goes for Emergency Use Approval in the US.
EMA recommends to continue AZD1222 vaccinations
/in News/by Thomas GabrielczykOn Tuesday, Emer Cooke had already hinted at it. Now the EMA’s PRAC committee confirmed: the benefits of AZ1222 by far outweigh the risks of the COVID-19 vaccine.